210 related articles for article (PubMed ID: 32146375)
1. Design and synthesis of tripeptidyl furylketones as selective inhibitors against the β5 subunit of human 20S proteasome.
Sun Q; Zhou T; Xi D; Li X; Lü Z; Xu F; Wang C; Niu Y; Xu P
Eur J Med Chem; 2020 Apr; 192():112160. PubMed ID: 32146375
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological evaluation of novel tripeptidyl epoxyketone derivatives constructed from β-amino acid as proteasome inhibitors.
Zhang J; Cao J; Xu L; Zhou Y; Liu T; Li J; Hu Y
Bioorg Med Chem; 2014 Jun; 22(11):2955-65. PubMed ID: 24767818
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel phenol ether derivatives as non-covalent proteasome inhibitors.
Yu J; Xu L; Hong D; Zhang X; Liu J; Li D; Li J; Zhou Y; Liu T
Eur J Med Chem; 2019 Jan; 161():543-558. PubMed ID: 30391816
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
[TBL] [Abstract][Full Text] [Related]
9. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
[TBL] [Abstract][Full Text] [Related]
12. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
13. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.
Miller Z; Kim KS; Lee DM; Kasam V; Baek SE; Lee KH; Zhang YY; Ao L; Carmony K; Lee NR; Zhou S; Zhao Q; Jang Y; Jeong HY; Zhan CG; Lee W; Kim DE; Kim KB
J Med Chem; 2015 Feb; 58(4):2036-41. PubMed ID: 25658656
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of some novel naphthoquinone-glycine/β-alanine anilide derivatives as noncovalent proteasome inhibitors.
Tatar I; Uysal S; Yilmaz S; Tarikogullari AH; Ballar Kirmizibayrak P; Soyer Z
Chem Biol Drug Des; 2023 Jun; 101(6):1283-1298. PubMed ID: 36762979
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]